BU-32: a novel proteasome inhibitor for breast cancer

INTRODUCTION: Proteasome inhibition provides an attractive approach to cancer therapy and may have application in the treatment of breast cancer. However, results of recent clinical trials to evaluate the effect of the proteasome inhibitor Bortezomib (Velcade(®), also called PS-341) in metastatic br...

Descripción completa

Detalles Bibliográficos
Autores principales: Agyin, Joseph K, Santhamma, Bindu, Nair, Hareesh B, Roy, Sudipa S, Tekmal, Rajeshwar R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790855/
https://www.ncbi.nlm.nih.gov/pubmed/19821999
http://dx.doi.org/10.1186/bcr2411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790855/
https://www.ncbi.nlm.nih.gov/pubmed/19821999
http://dx.doi.org/10.1186/bcr2411

Ejemplares similares